[go: up one dir, main page]

AR070898A1 - Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 - Google Patents

Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6

Info

Publication number
AR070898A1
AR070898A1 ARP090100917A ARP090100917A AR070898A1 AR 070898 A1 AR070898 A1 AR 070898A1 AR P090100917 A ARP090100917 A AR P090100917A AR P090100917 A ARP090100917 A AR P090100917A AR 070898 A1 AR070898 A1 AR 070898A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
optionally substituted
substituents
defined above
Prior art date
Application number
ARP090100917A
Other languages
English (en)
Inventor
Loevezijn Arnold Van
Bakker Wouter I Iwema
Cornelis G Kruse
Axel Stoit
Der Neut Martina A W Van
Jennifer Venhorst
Haan Martin De
Agatha A M Rensink
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR070898A1 publication Critical patent/AR070898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a derivados de arilsulfonil pirazolin carboxamidina como antagonistas de receptores 5-HT6, a métodos para la preparacion de estos compuestos y a novedosos intermediarios utiles para su síntesis. También se refiere a los usos de tales compuestos y composiciones particularmente su uso en la administracion de los mismos a pacientes para lograr un efecto terapéutico en la enfermedad de Parkinson, corea de Huntington, esquizofrenia, ansiedad, depresion, depresion maníaca, psicosis, epilepsia, trastornos obsesivos compulsivos, trastornos del ánimo, migrana, enfermedad de Alzheimer, declinacion cognitiva relacionada con la edad, deterioro cognitivo leve, trastornos del sueno, trastornos de la alimentacion, anorexia, bulimia, trastornos de atracones en la alimentacion, ataques de pánico, acatisia, trastorno de hiperactividad y déficit de atencion, trastorno de déficit de atencion, abstinencia del abuso de cocaína, etanol, nicotina o benzodiazepinas, dolor, trastornos asociados con trauma espinal o dano en la cabeza, hidrocefalia, trastorno funcional del intestino, síndrome de intestino irritable, obesidad y diabetes tipo 2. Reivindicacion 1: Un compuesto de la formula (1) o un tautomero, estereoisomero, N-oxido, o una sal farmacologicamente aceptable de cualquiera de los anteriores, en donde: R1 es elegido de hidrogeno o un grupo alquilo C1-4, opcionalmente sustituido con uno o más átomos de halogeno o un grupo hidroxilo, R2 y R3 son independientemente elegidos de hidrogeno, un grupo hidroxilo o un grupo alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes Q, independientemente elegidos de: halogeno, alquilo C1-4, alquenilo C1-4, alquinilo C1-4, CF3, NH2, NH-alquilo C1-4, N[alquilo C1-4]2, OH, =O, O-alquilo C1-4, o OCF3, o, R1y R2, junto con los átomos de carbono marcados 'a' y 'b' forman un anillo cicloalquilo C5-8, opcionalmente sustituido con uno o más átomos de halogeno, un grupo hidroxilo o un grupo alquilo C1-4, o, R2 y R3, junto con el átomo de carbono marcado 'b' forman un cicloalquilo C3-8 o un anillo heterocicloalquilo C4-8, opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, R4 y R5 son independientemente elegidos de hidrogeno o un grupo alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, o, R4 y R5 son independientemente elegidos de un grupo aromático o hetero-aromático, monocíclico o bicíclico fusionado, opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, con la condicion de que Q no puede ser =O (ceto) o anillos aromáticos, o R3 y R4, junto con los átomos de carbono marcados 'b' y 'c' forman un cicloalquilo C3-8 o un anillo heterocicloalquilo C5-8, opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, R6 y R7 son independientemente elegidos de hidrogeno, o un grupo alquilo C1-4 opcionalmente sustituido con uno o más átomos de halogeno o un grupo hidroxilo, o un grupo dialquil C1-3-amino-alquilo C1-3, o, R6 y R7 independientemente son elegidos de un grupo aromático o hetero-aromático, monocíclico o bicíclico fusionado, opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, o, R6 y R7 independientemente son un grupo cicloalquilo C5-8 o un grupo heterocicloalquilo C5-8 opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, o, R6 y R7, junto con el átomo de nitrogeno al cual están unidos, forman un grupo heterocicloalquilo C5-8 opcionalmente sustituido con uno o más sustituyentes Q, como se define anteriormente, R8 es elegido del grupo de formulas (2) en donde: el asterisco (*) marca el enlace al átomo de S, n es 0 (cero) o 1, el grupo (Het)Ar es un grupo arilo o heteroarilo, - X, Y y Z son independientemente elegidos de C, N, O o S, con el entendimiento que los enlaces en el anillo que contiene X, Y o Z pueden ser simples o dobles, y C y N están sustituidos solamente con átomos de H, R y R' son independientemente elegidos de halogeno, alquilo C1-4, alquenilo C1-4, alquinilo C1-4, CF3, NH2, NH-alquilo C1-4, N[alquilo C1-4]2, OH, SH, ceto, O- alquilo C1-4, S-alquilo C1-4, SO-alquilo C1-4, SO2-alquilo C1-4, OCF3, nitro y ciano, con la condicion de que cuando R1, R3, R4, R5 y R6 son hidrogeno, R2 y R7 son etilo, y R8 es 4-aminofenilo o 3-cloro-4-aminofenilo, los compuestos no son mezclas racémicas sino enantiomeros puros.
ARP090100917A 2008-03-18 2009-03-13 Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 AR070898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08152873 2008-03-18

Publications (1)

Publication Number Publication Date
AR070898A1 true AR070898A1 (es) 2010-05-12

Family

ID=39639064

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100917A AR070898A1 (es) 2008-03-18 2009-03-13 Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6

Country Status (29)

Country Link
US (3) US8563723B2 (es)
EP (2) EP2265589B1 (es)
JP (1) JP5504252B2 (es)
KR (1) KR101623357B1 (es)
CN (2) CN104003937A (es)
AR (1) AR070898A1 (es)
AU (1) AU2009226956C1 (es)
BR (1) BRPI0908738A8 (es)
CA (1) CA2717922A1 (es)
CO (1) CO6290679A2 (es)
CR (1) CR11742A (es)
DK (2) DK2610247T3 (es)
DO (2) DOP2010000276A (es)
EA (1) EA023176B1 (es)
EC (1) ECSP10010476A (es)
ES (2) ES2577867T3 (es)
HK (1) HK1201823A1 (es)
IL (1) IL207846A0 (es)
MX (1) MX2010010299A (es)
MY (1) MY155318A (es)
NZ (1) NZ587743A (es)
PH (1) PH12013502376A1 (es)
PL (2) PL2265589T3 (es)
PT (1) PT2610247T (es)
SG (1) SG183688A1 (es)
TW (1) TWI557110B (es)
UA (1) UA105629C2 (es)
WO (1) WO2009115515A1 (es)
ZA (1) ZA201006272B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
SG2014009609A (en) * 2011-08-15 2014-05-29 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
MX2015005720A (es) * 2012-11-16 2015-09-08 Bristol Myers Squibb Co Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
CN104918935B (zh) * 2012-11-16 2017-07-28 百时美施贵宝公司 二氢吡唑gpr40调节剂
CA2891574A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
AU2015255765A1 (en) * 2014-05-09 2016-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
MX2022004367A (es) 2019-10-09 2022-05-06 Bayer Ag Nuevos compuestos de heteroarilo-triazol como pesticidas.
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286988C2 (ru) * 2001-09-21 2006-11-10 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
TWI428334B (zh) * 2006-09-22 2014-03-01 Abbvie Bahamas Ltd 作為５-ｈｔ6拮抗劑之磺醯基吡唑及磺醯基吡唑啉的甲脒衍生物

Also Published As

Publication number Publication date
AU2009226956B2 (en) 2013-05-23
PH12013502376B1 (en) 2015-01-12
JP2011517443A (ja) 2011-06-09
DK2265589T3 (en) 2016-03-21
SG183688A1 (en) 2012-09-27
MY155318A (en) 2015-09-30
CN102036967B (zh) 2014-10-15
AU2009226956A8 (en) 2010-09-23
DOP2010000277A (es) 2011-01-31
EP2610247A1 (en) 2013-07-03
PL2265589T3 (pl) 2016-06-30
JP5504252B2 (ja) 2014-05-28
PL2610247T3 (pl) 2017-02-28
AU2009226956A1 (en) 2009-09-24
PT2610247T (pt) 2016-07-07
ZA201006272B (en) 2011-05-25
US8563723B2 (en) 2013-10-22
ES2577867T3 (es) 2016-07-19
CR11742A (es) 2011-03-03
DOP2010000276A (es) 2010-11-15
US20110046171A1 (en) 2011-02-24
EA023176B1 (ru) 2016-05-31
DK2610247T3 (en) 2016-06-13
EP2265589B1 (en) 2016-01-27
US9126942B2 (en) 2015-09-08
EA201071083A1 (ru) 2011-04-29
EP2265589A1 (en) 2010-12-29
US20140011775A1 (en) 2014-01-09
CO6290679A2 (es) 2011-06-20
HK1201823A1 (en) 2015-09-11
CN104003937A (zh) 2014-08-27
MX2010010299A (es) 2010-12-15
US8901108B2 (en) 2014-12-02
BRPI0908738A2 (pt) 2017-06-13
HK1152708A1 (en) 2012-03-09
ES2565184T3 (es) 2016-04-01
AU2009226956C1 (en) 2014-03-06
TW200942519A (en) 2009-10-16
IL207846A0 (en) 2010-12-30
PH12013502376A1 (en) 2015-01-12
TWI557110B (zh) 2016-11-11
UA105629C2 (uk) 2014-06-10
CN102036967A (zh) 2011-04-27
US20150051239A1 (en) 2015-02-19
WO2009115515A1 (en) 2009-09-24
KR20100136504A (ko) 2010-12-28
ECSP10010476A (es) 2010-10-30
BRPI0908738A8 (pt) 2017-10-10
NZ587743A (en) 2012-06-29
CA2717922A1 (en) 2009-09-24
EP2610247B1 (en) 2016-05-25
KR101623357B1 (ko) 2016-05-23

Similar Documents

Publication Publication Date Title
AR070898A1 (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
AR062907A1 (es) Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6
AU2002237654B2 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
HRP20140687T1 (hr) Derivati benzofurana
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
WO2014053409A1 (en) Benzimidazol.es as cns active agents
AR070635A1 (es) DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.
JP2007500168A5 (es)
AR074558A1 (es) Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
MX2015014353A (es) Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
PH12012500867A1 (en) Ethynyl derivatives
MX2012002256A (es) Antagonistas carbociclicos de receptores de inhibidores de transportador de glicina 1 (glty1).
RU2011103759A (ru) Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
AR067873A1 (es) Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3
ATE455113T1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors
MX2016001080A (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).

Legal Events

Date Code Title Description
FB Suspension of granting procedure